Age de-escalation study to assess safety and immunogenicity of recombinant E. coli BK-SE36 malaria vaccine candidate formulated with CpG adjuvant administered intramuscularly in healthy malaria exposed African adults and children living in Burkina Faso.

Trial Profile

Age de-escalation study to assess safety and immunogenicity of recombinant E. coli BK-SE36 malaria vaccine candidate formulated with CpG adjuvant administered intramuscularly in healthy malaria exposed African adults and children living in Burkina Faso.

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs Malaria vaccine (Primary)
  • Indications Malaria
  • Focus Adverse reactions
  • Sponsors Nobelpharma
  • Most Recent Events

    • 21 Aug 2017 Planned initiation date changed from 30 Jun 2017 to 30 Sep 2017.
    • 07 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top